Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard ...

Next year could be a very different one for stockpickers.Investors have piled into a range of companies with exposure to artificial intelligence this year, helping spawn a boom in a range of ...

Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice ...

B of A Securities analyst Tim Anderson upgraded Bristol-Myers Squibb Co (NYSE: BMY) from Neutral to Buy and raised the price ...

In recent days, Bristol Myers Squibb’s board approved a 1.6% increase in its quarterly common dividend to US$0.63 per share ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Looking toward dividend payers is a particularly good idea, because companies that consistently increase their payouts tend ...